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A novel 96-microwell-based high-throughput spectrophotometric 
assay for pharmaceutical quality control of crizotinib, a novel 
potent drug for the treatment of non-small cell lung cancer
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This study describes the development and validation of a novel 96-microwell-based high throughput 
spectrophotometric assay for pharmaceutical quality control of crizotinib (CZT), a novel drug for the 
treatment of non-small cell lung cancer. We examined the reaction between CZT and 1,2-naphthoquinone-
4-sulphonate, a chromogenic reagent. A red-colored product showing a maximum absorption peak (λmax) 
at 490 nm was produced in an alkaline medium (pH 9). We examined stoichiometry of the reaction and 
postulated the reaction mechanism. To our knowledge, this is the first study to describe a color-developing 
reaction for the proposed assay. The reaction was performed in a 96-microwell plate, and the absorbance 
of the colored product was measured using an absorbance reader at 490 nm. Under optimized reaction 
conditions, Beer’s law, which shows a correlation between absorbance and CZT concentration, was 
obeyed in the range of 4–50 µg/well with an appropriate correlation coefficient (0.999). The limits of 
detection and quantification were 1.73 and 5.23 µg/well, respectively. The assay showed high precision 
and accuracy. The proposed assay was applied successfully for the determination of CZT in capsules. 
Thus, the assay proposed in this study is practical and valuable for routine application in pharmaceutical 
quality control laboratories.
Uniterms: Crizotinib/capsules/quality control. 1,2-Naphthoquinone-4-sulphonate. Spectrophotometry/
quality control of medicines.
Este estudo descreve o desenvolvimento e a validação de um novo ensaio espectrofotométrico em 
larga escala em 96 micropoços para o controle farmacêutico de crizotinibe (CZT), novo fármaco para 
o tratamento de câncer de pulmão de células não pequenas. Examinamos a reação entre o CZT e o 
4-sulfonato de 1,2-naftoquinona, um reagente cromogênico. Obteve-se, em meio alcalino (pH 9), produto 
vermelho, com absorção máxima (λmax) em 490 nm. Examinamos a estequiometria da reação e propusemos 
mecanismo de reação. Este, segundo nosso conhecimento, é o primeiro estudo para descrever reação de 
desenvolvimento de cor para o ensaio proposto. A reação foi realizada em placas de 96 micropoços e 
mediu-se a absorbância do produto colorido utilizando-se leitor de absorbância a 490 nm. Sob condições 
otimizadas de reação, a lei de Beer, que mostra a correlação entre a absorbância e a concentração de CZT, 
foi obedecida na faixa de 4–50 µg/poço, com coeficiente de correlação apropriado (0,999). Os limites de 
detecção e de quantificação foram, respectivamente, 1,73 e 5,23 µg/poço. O ensaio mostrou alta precisão 
e exatidão. O ensaio proposto foi aplicado com sucesso para a determinação de CZT em cápsulas e é 
prático e válido para a aplicação de rotina em laboratórios de controle farmacêutico.
Unitermos: Crizotinibe/cápsulas/controle de qualidade. 4-Sulfonato de 1,2-naftoquinona. 
Espectrofotometria/controle de qualidade de medicamentos.
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INTRODUCTION
Lung cancer is the most common cancer worldwide 
in men and women in terms of both incidence and 
mortality. In 2008, there were 1.61 million new cases 
and 1.38 million deaths because of lung cancer (WHO, 
2005; Ferlay et al., 2010). The most common causes of 
lung cancer are air pollution, genetic factors, and long-
term exposure to tobacco smoke, radon gas, and asbestos 
(O’Reilly et al., 2007). Most primary lung carcinomas 
are derived from epithelial cells. The main types of lung 
cancers are small-cell lung cancer and non-small cell lung 
cancer (NSCLC). NSCLC accounts for approximately 
85% of all lung cancers. These cancer cells grow quickly 
and spread early in the course of the disease. Surgery, 
radiotherapy, and chemotherapy are the main treatment 
options for NSCLC. Surgery and radiotherapy are 
usually considered for localized stage I and stage II of 
NSCLC; however, these treatment options are not feasible 
for advanced NSCLC (Strand et al., 2011; Rowell, 
Williams, 2001; Stand et al., 2011). Chemotherapy is the 
treatment of choice for approximately 80% of all patients 
with NSCLC (Tan et al., 2013). Multiple randomized 
controlled trials and large meta-analyses have confirmed 
the superiority of chemotherapy regimens for advanced 
NSCLC (NSCLC, 2008; NSCLC, 2013). Chemotherapy is 
used as the first-line treatment for patients with advanced 
metastatic or localized NSCLC, and it improves the 
survival and quality of life if the patient is well enough 
for the treatment (Burdett et al., 2008; NSCLC, 2010). 
Typically, first-generation tyrosine kinase inhibitors 
(e.g., gefinitinib and erlotinib) have been used for the 
treatment of NSCLC (Cohen et al., 2004; Johnson et al., 
2005). A considerable number of NSCLC patients have a 
chromosomal rearrangement that generates a fusion gene 
between echinoderm microtubule-associated protein like 
4 (EML4) and anaplastic lymphoma kinase (ALK), which 
results in constitutive kinase activity that contributes to 
increased cell carcinogenesis and drives the malignant 
phenotype (Tan, Harris, Huq, 2013; Ron, 2010; Pfizer 
Oncology, 2014 (Link com erro, data corresponde ao dia 
do acesso e não a data do documento). Patients with this 
fusion gene are typically young non-smokers who do 
not have mutations in either the epidermal growth factor 
receptor (EGFR) gene or in the K-Ras gene (Alberg, 
Samet, 2010 (falta referência); O’Reilly et al., 2007). 
First-generation tyrosine kinase inhibitors do not inhibit 
the kinase activity of the fusion protein, and thus, studies 
were performed to discover an alternative novel drug for 
the treatment of patients with NSCLC, including those 
with tumors harboring EML4-ALK fusion proteins.
Crizotinib (CZT; Figure 1) is a novel small-molecule 
inhibitor of tyrosine kinase. CZT acts by competitive 
binding with the ATP-binding pocket of target kinases 
(Sai-Hong, 2011(falta referência); Rodig, Shapiro, 2010; 
Kwak et al., 2010; Cui et al., 2011). CZT causes tumor 
shrinkage in 90% of patients carrying the ALK fusion gene 
(Kris, 2011 (na referência a data é 2011). On the basis of 
two successful clinical multi-center studies, CZT was 
granted an accelerated approval by the Food and Drug 
Administration (FDA) on August 26, 2011 (under the 
trade name of Xalkori® capsules made by Pfizer, Inc.) for 
the treatment of patients with advanced local or metastatic 
NSCLC that is ALK-positive as detected by the FDA-
approved test (Abbot Molecular, Inc.) (NIH,, 2011). 
Effective and safe therapy with CZT mainly depends 
on the quality of its pharmaceutical formulation (Xalkori 
capsules). For the pharmaceutical quality control (QC) 
of CZT, a proper analytical method with high throughput 
is required. Previous studies showed that to date, no 
analytical method is available for the determination of 
CZT in its bulk or in capsules. Spectrophotometry has 
considerable importance in drug analysis, and photometric 
methods are extensively applied for the determination 
of active substances in bulk drugs and pharmaceutical 
preparations (Görög, 1994). However, the conventional 
spectrophotometric methods are not automated and their 
throughputs are low; thus, their practical applications in 
pharmaceutical QC laboratories are limited. 
In this study, we described the development of a new 
96-microwell-based high-throughput spectrophotometric 
assay for the QC of CZT. This assay was based on the 
reaction of CZT with 1,2-naphthoquinone-4-sulphonate 
(NQS) in an alkaline buffered medium to produce a 
red-colored product. The reaction was performed in 
a 96-microwell assay plate, and the absorbance was 
measured using a microwell-plate absorbance reader.
MATERIAL AND METHODS
Apparatus
A microwell-plate absorbance reader (ELx 808; Bio-
Tek Instruments Inc., Winooski, USA) empowered by the 
Gen5 software (provided with the instrument) was used 
for all the measurements in 96-microwell plates. UV-1601 
PC double-beam ultraviolet-visible spectrophotometer 
(Shimadzu, Kyoto, Japan) with matched 1-cm quartz 
cells was used for recording the absorption spectra. We 
used a pH meter model 350 from Bibby Scientific Ltd., 
T/As Jenway, Essex, England. 96-Microwell plates were 
purchased from Corning/Costar Inc. (Cambridge, USA). 
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Finnpipette adjustable 8-channel-pipette was purchased 
from Sigma Chemical Co. (St. Louis, MO, USA).
Reagents and materials
CZT was purchased from Haoyuan Chemexpress 
Co., Ltd. (Shanghai, China) and used as received; the 
purity of the investigated compound was >99%, and 
the solution was stable for at least one month when kept 
refrigerated. An aqueous solution (0.1%, w/v) of NQS 
(Aldrich Chemical Co., St. Louis, USA) was freshly 
prepared and protected from light during use. Buffer 
solutions (Clark, tris, phthalate, borate, phosphate, 
and carbonate) were prepared as previously described 
(Pesez, Bartos, 1974). We used Xalkori capsules (Pfizer 
Inc., New York, NY, USA) labeled to contain 250 mg 
CZT per capsule. Double distilled water was obtained 
using the WSC-85 water purification system (Hamilton 
Laboratory Glass Ltd., Kent, USA) and used throughout 
the experiment. All solvents and materials used in this 
study were of analytical grade.
Preparation of solutions
Standard CZT solution
An accurately weighed amount (25 mg) of CZT was 
quantitatively transferred into a 25-mL calibrated flask, 
dissolved in 20 mL methanol, completed to volume with 
the same solvent to obtain a stock solution of 1 mg/mL. 
The stock solution was stable for at least two weeks when 
under refrigerated conditions. The stock solution was 
further diluted with methanol to obtain working solutions 
in the range of 4–50 μg/well (50 mL).
Capsule sample solution
The contents of 10 Xalkori capsules were emptied 
and weighed. An accurately weighed quantity of the 
capsule contents equivalent to 25 mg of CZT was 
transferred into a 25-mL calibrated flask and dissolved in 
15 mL of methanol. The contents of the flask were swirled, 
sonicated for 20 min, and then, completed to volume with 
methanol. The contents were mixed well and centrifuged 
at 6000 rpm for 10 min; the supernatant was separated and 
filtered, and the first portion of the filtrate was rejected. The 
filtered solution was diluted quantitatively with methanol 
to obtain suitable concentrations for analysis using the 
proposed assay. 
General recommended assay procedures
An accurately measured volume (50 mL) of CZT 
solution containing 4–50 μg/well (50 mL) was transferred 
into a 96-microwell plate. Subsequently, we added 25 mL 
of Clark’s buffer solution, pH 9, and 50 mL of NQS solution 
(0.1%, w/v). The reaction was allowed to proceed for 
15 min at room temperature (25 ± 2 °C), and then, 100 mL 
of methanol was added to each well. The absorbance of 
the resulting solution was measured at 490 nm.
Determination of the molar ratio of NQS:CZT
We prepared  master  so lu t ions  of  varying 
concentrations of NQS (0.025-4×10-3 mol/L) and a CZT 
solution of a fixed concentration (1×10-3 mol/L). Then, 
we transferred an accurately measured volume (50 mL) 
of the CZT solution into each well of the 96-microwell 
plate followed by the addition of 25 mL Clark’s buffer 
solution, pH 9. Further, we added 50-mL aliquots of 
varying concentrations of NQS solution to the microwell-
assay plate to prepare various molar ratios of NQS:CZT 
(4-1). The reaction solutions were further manipulated as 
described in the general recommended assay procedures. 
The measured absorbances were plotted as a function 
of the NQS:CZT molar ratio. The plot was used for the 
determination of the molar ratio of the reaction between 
CZT and NQS. 
RESULTS AND DISCUSSION
Strategy for assay development and its design
We recorded the absorption spectrum of CZT 
solution (50 mg/mL, in methanol) (Figure 1). The 
absorption spectrum showed that CZT has two maximum 
absorption peaks (λmax) at 270 and 320 nm. These 
blue-shifted λmax introduce potential interference in the 
spectrophotometric assay for QC of CZT based on its 
native UV light absorption from the excipients in its dosage 
form (capsules). Therefore, development of a visible 
spectrophotometric assay for CZT is important. This assay 
enables the use of simple inexpensive instruments that are 
equipped with color measuring detection systems that are 
available in most QC laboratories. Therefore, in this study, 
we developed a visible spectrophotometric assay for the 
determination of CZT in bulk and capsules. 
For the development of a visible spectrophotometric 
assay for CZT, a color-developing reaction was required. 
CZT contains a piperazinyl amino group and a primary 
aromatic amino group; thus, many reagents can be used 
for the color-producing reaction (Görög, 1994; Toyo’oka, 
1999). These reactions involve formation of colored 
charge-transfer complexes with electron acceptors, 
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formation of ion-pair associates with pairing reagents, 
and formation of condensation products with chromogenic 
reagents. These methods are usually associated with some 
major drawbacks such as laborious multiple extraction 
steps in the analysis using ion-pair based methods, 
consumption of large volumes of organic solvents in ion-
pair- and charge transfer-based methods, and long time 
required for some condensation reactions. Therefore, in 
this study, we aimed to develop an alternative simple color 
reaction for quantification of CZT using a new visible 
spectrophotometric assay. 
Previously, Darwish et al. (2009,2012) showed that 
NQS is a convenient and valuable color-developing reagent 
in the development of simple spectrophotometric methods 
for the determination of many pharmaceutical amines. The 
reaction between CZT and NQS has not been investigated 
thus far. The CZT molecule has two anticipated reactive 
centers, which are the piperazinyl amino group and the 
primary aromatic amino group. Therefore, we investigated 
the reaction between NQS and CZT, and the use of this 
color reaction in the development of a new simple and 
rapid high-throughput spectrophotometric assay for the 
determination of CZT in bulk and capsules. 
The reaction between CZT and NQS was performed 
in a 96-microwell assay plate (200-µL total reaction 
volume). The solutions were dispensed using an 8-channel 
pipette, and the absorbance of the colored-reaction product 
was measured using a 96-microwell-plate absorbance 
reader. We used the 96-microwell design in this assay 
on the basis of the previous studies by Darwish et al. 
(2013, 2014) for high-throughput analysis of some other 
pharmaceuticals. These studies are described below. 
Absorption spectra and optimization of reaction 
conditions
The reaction between CZT and NQS was performed, 
and the absorption spectrum of the reaction product was 
recorded against reagent blank. The reaction product was 
red colored and showed λmax at 490 nm depending on CZT 
concentrations (Figure 1). The experimental conditions 
affecting the reaction in the 96-microwell format were 
optimized by altering each reaction variable in a turn while 
keeping the others constant. 
The absorbance of the reaction product between NQS 
and CZT increased with an increase in the concentration 
NQS (Figure 2A). The highest value was obtained 
at a concentration of 0.08% (w/v); the absorbance 
values remained constant beyond this concentration. A 
concentration of 0.1% (w/v) was used in all the subsequent 
experiments.
The influence of pH on the reaction of CZT with 
NQS was investigated by performing the reaction in a 
buffer solution of varying pH values (pH 7–10). The results 
showed that the reaction was dependent on the pH because 
the absorbance increased with pH, and the maximum value 
of absorbance was observed in the pH range of 8.5–10 
(Figure 2B). A high reactivity was observed at an alkaline 
pH because the alkaline pH did not alter the amino group 
of CZT, and thus, facilitated nucleophilic substitution 
with the NQS reagent. All subsequent experiments were 
performed at pH 9. To investigate the effect of the buffer 
components on the reaction, we examined different buffer 
solutions adjusted at pH 9 as follows: Clark’s, carbonate, 
phosphate, borate, phathalate, and tris buffers. The highest 
readings were obtained when Clark’s buffer was used (data 
not shown); therefore, we used Clark’s buffer for all the 
subsequent experiments. 
To determine the optimum time required for the 
completion of the reaction, we allowed the reaction to 
proceed at room temperature for different periods of time. 
We observed that the reaction was almost completed within 
10 min (Figure 2C); however, to obtain readings with a high 
precision, the reaction was allowed to proceed for 15 min. 
A summary of the optimum conditions for the 
reaction between CZT and NQS is given in Table I.
Stoichiometry and mechanism of the reaction
Under the optimum conditions (Table I), we 
determined the stoichiometry of the reaction between CZT 
and NQS. We observed that the CZT:NQS ratio was 1:2 
(Figure 2D). This indicated that two sites of interaction 
FIGURE 1 - Absorption spectra of crizotinib (CZT) against 
methanol, 1,2-naphthoquinone-4-sulphonate (NQS) against 
water, and CZT-NQS reaction product at varying CZT 
concentrations against reagent blank. 
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TABLE 1 - Summary of the optimization of variables affecting the 
reaction between CZT and NQS reagent used in the development 
of the proposed 96-microwell-based spectrophotometric assay 
for crizotinib (CZT)
Variable Studied range Optimum
NQS concentration 
(%, w/v)
0.01– 0.25 0.1
pH 7 –10 9
Time (min) 5–45 15
Measuring 
wavelength (nm)
400–650 490
FIGURE 2 - Effect of different 1,2-naphthoquinone-4-sulphonate (NQS) concentrations (A), pH (B), and time (C) on the reaction 
between crizotinib (CZT) and NQS, and the reaction molar ratio (D).
FIGURE 3 - Proposed mechanism of the reaction between 
crizotinib (CZT) and 1,2-naphthoquinone-4-sulphonate (NQS).
on the CZT molecule were involved in the formation of 
the colored CZT-NQS product, and two NQS molecules 
were required for the formation of the reaction product. 
These two sites were the piperazinyl amino group and 
the primary aromatic amino group. On the basis of these 
results, we postulated the reaction pathway (Figure 3).
Validation of the assay
Calibration and sensitivity
Under the optimum reaction conditions (Table I), 
we constructed the calibration curve for determining 
the CZT concentration upon its reaction with NQS by 
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plotting the absorbances as a function of the corresponding 
concentrations (Figure 4). The regression equation for 
the results was A = 0.0085 + 0.0370 C (r = 0.999), where 
A is the absorbance at 490 nm, C is the concentration of 
CZT in µg/well in the range of 4-50 µg/well, and r is the 
correlation coefficient. The limit of detection (LOD) and 
limit of quantification (LOQ) were determined according 
to the International Conference of Harmonization (ICH) 
guidelines for validation of analytical procedures (ICH, 
1996). We used the following: LOD or LOQ = ×SDa/b, 
where × = 3.3 for LOD and 10 for LOQ, SDa is the 
standard deviation of the intercept, and b is the slope. 
The LOD and LOQ were 1.73 and 5.23 µg/well, 
respectively. 
The parameters for the analytical performance of the 
proposed method are summarized in (Table II).
Precision
The intra-assay precision of the proposed method 
was determined using different concentrations of the drug 
solution and analyzing 6 replicates of each concentration as 
a batch in a single assay run. The inter-assay precision was 
determined by analyzing the same samples as duplicates 
on three consecutive days. The relative standard deviations 
(RSD) did not exceed 2%, which proved the high precision 
of the proposed assay for routine application in the analysis 
of CZT in QC laboratories. 
Accuracy, selectivity, and interference liabilities
The accuracy of the proposed assay was evaluated by 
determining the recovery rates of different concentrations 
of CZT. The recovery values were 98.2-99.7 ± 1.24-1.79%, 
which indicated the accuracy of the proposed assay. 
The advantages of the proposed assay are that the 
measurements are performed in the visible region, away 
from the UV-absorbing interfering substances that might 
be co-extracted from dosage forms containing CZT. 
Before analyzing the amount of CZT in its dosage form 
(capsules), interference liabilities were performed to 
explore the effect of inactive ingredients that might be 
added during formulation of CZT capsules (Xalkori, 
2013). The samples were prepared by mixing a known 
amount (250 mg) of CZT with 50 mg of microcrystalline 
cellulose, 10 mg of colloidal silicon dioxide, 5 mg of 
anhydrous dibasic calcium phosphate, 5 mg of sodium 
starch glycolate, and 5 mg of magnesium stearate. These 
laboratory-prepared samples were analyzed using the 
proposed method by applying the general recommended 
procedure. The recovery values ranged from 96.2 ±  1.04 
to 102.1 ± 1.46% (Table III). These data confirmed 
the absence of interference from any of the inactive 
ingredients during the determination of CZT by using the 
proposed assay.
Application for analysis of CZT in capsules
Our results indicate that the proposed method 
yielded satisfactory results with CZT in bulk powder. 
Further, we used this method for the determination of CZT 
concentration in its pharmaceutical dosage form (Xalkori 
capsules). The percentage found from the label claim was 
99.82 ± 1.24%. The good recovery values indicated the 
reliability of the proposed assay for routine application 
for the accurate determination of CZT in pharmaceutical 
QC laboratories. 
FIGURE 4 - Calibration curve for the determination of 
crizotinib (CZT) concentration by using the 96-microwell 
spectrophotometric assay on the basis of its reaction with 
1,2-naphthoquinone-4-sulphonate (NQS).
TABLE II  - Quantitative parameters for the analytical performance 
of the proposed 96-microwell-based spectrophotometric assay 
for crizotinib (CZT)
Parameter Value 
Linear range (mg/well) 4-50
Intercept (a) 0.0085
Standard deviation of the intercept 0.0194
Slope 0.0370
Correlation coefficient 0.999
Limit of detection, LOD (mg/well) 1.73
Limit of quantification, LOQ (mg/well) 5.23
Precision (RSD, %) <2
Accuracy (recovery, %) >98
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CONCLUSIONS
This study described the successful development of 
a new 96-microwell-based spectrophotometric assay for 
the accurate determination of CZT in its bulk and capsules 
based on its derivatization with NQS as a chromogenic 
analytical reagent. The assay described herein offered the 
following advantages:
-	This method uses an inexpensive, stable reagent 
with excellent shelf life, and the reagent is available in any 
pharmaceutical QC laboratory. 
-	This method provides a high-throughput analytical 
method that can be used to analyze a large number of 
samples in a relatively short time. This property was 
attributed to using multi-channel pipettes for efficient 
dispensing of the solutions, performing the analytical 
reaction in 96-well plates (as reaction vessels), and 
measuring the color signals in the 96 wells at ~30 s using 
the plate reader. 
-	This method used minimum volumes of reagent 
and organic solvents (environmentally friendly “Green” 
approach), and thus, decreased cost of analysis and the 
exposures of the analysts to the toxic effects of organic 
solvents. 
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TABLE III - Analysis of crizotinib (CZT) in presence of excipients 
present in its capsules by using the proposed 96-microwell-based 
spectrophotometric assay
Excipient Recovery (% ± SD)
Microcrystalline cellulose (50)a 101.4 ± 1.25
Colloidal silicon dioxide (10)  96.2 ± 1.04
Anhydrous dibasic calcium 
phosphate (5)
 98.9 ± 1.31
Sodium starch glycolate (5) 102.1 ± 1.46
Magnesium stearate (5)  99.7 ± 0.87
a Values are mean of three determinations. b Figures in 
parenthesis are the amounts (in mg) that were added per 250 
mg of CZT. 
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